Arcutis Biotherapeutics, Inc.ARQTNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +17.44% | +427.58% | +32.84% | +164.13% | +121.69% |
| Gross Profit Growth | +6.30% | +471.41% | +23.11% | +170.18% | +130.65% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +101.37% | +30.65% | +13.50% | +2.85% | +2.67% |
| Weighted Average Shares Diluted Growth | +101.37% | +30.65% | +13.50% | +2.85% | +6.90% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +209.62% | +183.12% | +129.89% | +145.76% | +91.48% |
| Inventory Growth | +0.73% | +10.60% | +25.42% | +17.61% | +59.96% |
| Asset Growth | +49.29% | +2.20% | -28.09% | -20.76% | -15.18% |
| Book Value per Share Growth | +66.51% | +35.99% | -44.12% | -27.52% | -1.71% |
| Debt Growth | +1.52% | -46.30% | -46.41% | -46.93% | -45.35% |
| R&D Expense Growth | -25.67% | -39.10% | -24.19% | +0.80% | +0.53% |
| SG&A Expenses Growth | +23.58% | +18.35% | +16.80% | +18.90% | +6.10% |